Replimune Group Files 8-K for Regulation FD Disclosure

Ticker: REPL · Form: 8-K · Filed: 2025-06-24T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, regulation-fd

TL;DR

Replimune Group filed an 8-K for a Reg FD disclosure on June 24, 2025.

AI Summary

On June 24, 2025, Replimune Group, Inc. filed an 8-K report. The filing indicates that the company is providing a Regulation FD Disclosure. No specific financial figures or material events beyond this disclosure type are detailed in the provided text.

Why It Matters

This filing signals that Replimune Group, Inc. is making a public disclosure under Regulation FD, which ensures all investors receive material information at the same time.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain information about significant financial changes, legal issues, or operational disruptions.

Key Players & Entities

Replimune Group, Inc. (company) — Registrant
June 24, 2025 (date) — Date of earliest event reported
Regulation FD (regulation) — Type of disclosure

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide a Regulation FD Disclosure.

What is the exact name of the registrant?

The exact name of the registrant is Replimune Group, Inc.

On what date was the earliest event reported?

The earliest event reported was on June 24, 2025.

What is the principal executive office address of Replimune Group, Inc.?

The address of the principal executive offices is 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801.

What is the registrant's telephone number?

The registrant's telephone number is (781) 222-9600.

From the Filing

0001104659-25-062122.txt : 20250624 0001104659-25-062122.hdr.sgml : 20250624 20250624163037 ACCESSION NUMBER: 0001104659-25-062122 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250624 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20250624 DATE AS OF CHANGE: 20250624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 251069615 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 tm2518774d1_8k.htm FORM 8-K false 0001737953 0001737953 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  June 24, 2025       REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38596   82-2082553 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)   500 Unicorn Park Drive Suite 303 Woburn , MA 01801 (Address of principal executive offices, including Zip Code)   Registrant’s telephone number, including area code: ( 781 ) 222-9600   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   REPL   The Nasdaq Stock Market LLC (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨               Item 7.01 Regulation FD Disclosure .   As previously announced, Replimune Group, Inc. (the “Company”) hosted an Investor Day on Tuesday, June 24, 2025 at 10:00 a.m. ET. The audio webcast and accompanying updated investor event presentation deck is available under “Events and Presentations” in the Investors and Media section of the Company’s website at www.replimune.com.   In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Secti